Literature DB >> 24238640

Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.

Judith Neukirchen1, Michael Lauseker2, Sabine Blum3, Aristoteles Giagounidis4, Michael Lübbert5, Samuela Martino6, Sergio Siragusa6, Richard F Schlenk7, Uwe Platzbecker8, Wolf-Karsten Hofmann9, Katharina Götze10, Giuseppe A Palumbo11, Silvana Magrin12, Andrea Kündgen13, Carlo Aul4, Barbara Hildebrandt14, Joerg Hasford2, Guido Kobbe13, Rainer Haas13, Ulrich Germing13.   

Abstract

The revised IPSS (IPSS-R) was developed aiming at a better prognostication, taking into account patients treated with best supportive care. We herein validated this model on the basis of data from 1314 patients who received BSC only as well as patients who underwent induction chemotherapy (n=214) or allogeneic transplantation (n=167). We could demonstrate a clear distinction of the IPSS-R risk categories with regard to survival and risk of AML evolution in all patient cohorts. When comparing IPSS-R, IPSS, WHO prognostic scoring system (WPSS) and Duesseldorf score, the best results regarding the ability to predict survival were obtained by the IPSS-R.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  IPSS; IPSS-R; MDS; Prognosis; Survival; WPSS

Mesh：

Year:  2013        PMID： 24238640     DOI： 10.1016/j.leukres.2013.10.013

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  23 in total

1.  Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).

Authors:  M G Della Porta; H Tuechler; L Malcovati; J Schanz; G Sanz; G Garcia-Manero; F Solé; J M Bennett; D Bowen; P Fenaux; F Dreyfus; H Kantarjian; A Kuendgen; A Levis; J Cermak; C Fonatsch; M M Le Beau; M L Slovak; O Krieger; M Luebbert; J Maciejewski; S M M Magalhaes; Y Miyazaki; M Pfeilstöcker; M A Sekeres; W R Sperr; R Stauder; S Tauro; P Valent; T Vallespi; A A van de Loosdrecht; U Germing; D Haase; P L Greenberg; M Cazzola
Journal:  Leukemia       Date:  2015-02-27       Impact factor: 11.528

2.  Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes.

Authors:  R Martino; A Henseler; M van Lint; N Schaap; J Finke; D Beelen; S Vigouroux; E P Alessandrino; G J Mufti; J H Veelken; B Bruno; I Yakoub-Agha; L Volin; J Maertens; R Or; V Leblond; M Rovira; P Kalhs; A F Alvarez; A Vitek; J Sierra; E Wagner; M Robin; T de Witte; N Kröger
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

3.  Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.

Authors:  Friederike Braulke; Uwe Platzbecker; Catharina Müller-Thomas; Katharina Götze; Ulrich Germing; Tim H Brümmendorf; Florian Nolte; Wolf-Karsten Hofmann; Aristoteles A N Giagounidis; Michael Lübbert; Peter L Greenberg; John M Bennett; Francesc Solé; Mar Mallo; Marilyn L Slovak; Kazuma Ohyashiki; Michelle M Le Beau; Heinz Tüchler; Michael Pfeilstöcker; Thomas Nösslinger; Barbara Hildebrandt; Katayoon Shirneshan; Carlo Aul; Reinhard Stauder; Wolfgang R Sperr; Peter Valent; Christa Fonatsch; Lorenz Trümper; Detlef Haase; Julie Schanz
Journal:  Haematologica       Date:  2014-10-24       Impact factor: 9.941

4.  Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry.

Authors:  Hiroshi Kawabata; Kaoru Tohyama; Akira Matsuda; Kayano Araseki; Tomoko Hata; Takahiro Suzuki; Hidekazu Kayano; Kei Shimbo; Yuji Zaike; Kensuke Usuki; Shigeru Chiba; Takayuki Ishikawa; Nobuyoshi Arima; Masaharu Nogawa; Akiko Ohta; Yasushi Miyazaki; Kinuko Mitani; Keiya Ozawa; Shunya Arai; Mineo Kurokawa; Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2017-05-11       Impact factor: 2.490

5.  Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Ju-Whei Lee; Thomas Prebet; Peter Greenberg; Zhuoxin Sun; Mark Juckett; Mitchell R Smith; Elisabeth Paietta; Janice Gabrilove; Harry P Erba; Martin S Tallman; Steven D Gore
Journal:  Br J Haematol       Date:  2014-04-09       Impact factor: 6.998

6.  Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.

Authors:  Julie Waisbren; Shira Dinner; Jessica Altman; Olga Frankfurt; Irena Helenowski; Juehua Gao; Brandon J McMahon; Brady L Stein
Journal:  Int J Hematol       Date:  2016-08-24       Impact factor: 2.490

7.  Myelodysplastic syndromes, version 2.2015.

Authors:  Peter L Greenberg; Richard M Stone; Rafael Bejar; John M Bennett; Clara D Bloomfield; Uma Borate; Carlos M De Castro; H Joachim Deeg; Amy E DeZern; Amir T Fathi; Olga Frankfurt; Karin Gaensler; Guillermo Garcia-Manero; Elizabeth A Griffiths; David Head; Virginia Klimek; Rami Komrokji; Lisa A Kujawski; Lori J Maness; Margaret R O'Donnell; Daniel A Pollyea; Bart Scott; Paul J Shami; Brady L Stein; Peter Westervelt; Benton Wheeler; Dorothy A Shead; Courtney Smith
Journal:  J Natl Compr Canc Netw       Date:  2015-03       Impact factor: 11.908

Review 8.  Where Does Lenalidomide Fit in Non-del(5q) MDS?

Authors:  Aristoteles Giagounidis
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

9.  Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.

Authors:  Amer M Zeidan; Ju-Whei Lee; Thomas Prebet; Peter Greenberg; Zhuoxin Sun; Mark Juckett; Mitchell R Smith; Elisabeth Paietta; Janice Gabrilove; Harry P Erba; Rhett P Katterling; Martin S Tallman; Steven D Gore
Journal:  Br J Haematol       Date:  2014-07-04       Impact factor: 6.998

10.  Clinical and genetic predictors of prognosis in myelodysplastic syndromes.

Authors:  Rafael Bejar
Journal:  Haematologica       Date:  2014-06       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.